ALTERNATIVE: Dual HER2 Blockade + Aromatase Inhibitor in Postmenopausal Women With HER2+, HR+ MBC

Slideset - Significantly improved PFS and ORR observed with addition of lapatinib to trastuzumab plus investigator-selected aromatase inhibitor.
Source: Clinical Care Options Breast Cancer - Category: Cancer & Oncology Source Type: research